Brazil’s health regulator has approved the nation’s first domestically produced dengue vaccine, a significant development in the fight against the mosquito-borne illness that disproportionately impacts tropical regions [[1]]. developed by the Butantan Institute, the single-dose vaccine promises increased accessibility, particularly for remote communities, with over one million doses already prepared for distribution through the country’s public health system [[2]]. The vaccine, a result of collaboration with U.S. institutions including the NIH and ATCC [[3]], is currently authorized for use in individuals aged 12-59 and offers protection against all four dengue virus serotypes.
Brazil’s health regulatory agency has approved the country’s first domestically produced dengue vaccine, developed by the Butantan Institute. The landmark decision, announced on Monday, February 8, paves the way for production and distribution of the vaccine nationwide.
The vaccine will be made available through Brazil’s Unified Health System (SUS), ensuring broad access to the population. This approval marks a significant step forward in the fight against dengue fever, a major public health concern in Brazil and other tropical regions.
Currently, the vaccine is authorized for use in individuals between the ages of 12 and 59, with potential for expanded eligibility pending further research. The Butantan Institute initially requested registration for the single-dose vaccine in December 2024, and had already begun vaccine production prior to the Anvisa’s approval.
The new vaccine is tetravalent, meaning it provides protection against all four serotypes of the dengue virus. It underwent rigorous analysis to ensure its safety, quality, and effectiveness, adhering to all relevant health regulations. This is the first dengue vaccine to be produced by a national laboratory in Brazil.
According to Anvisa, the registration of the Butantan vaccine represents a crucial milestone in addressing the ongoing challenge of dengue in Brazil. The Institute will continue to conduct additional studies and actively monitor the vaccine’s performance in the general population following its rollout.
The vaccine utilizes a live-attenuated virus technology, a proven method already employed in numerous other vaccines used both in Brazil and globally. This technology is considered safe and effective for stimulating an immune response.
